What is Fujirebio’s vision for the future of blood-based biomarkers for neurological disorders, compared to its competitors? 

Due to a massive burden of an ageing population, escalating genetic mutations, abnormal protein accumulation, coupled with different environmental factors, vascular issues, & autoimmune responses, resulting in diverse neurological disorders. These disorders mainly affect the central or peripheral nervous system. These disorders affect crucial functions, particularly movement, memory, and breathing. Major symptoms are sudden severe headaches, muscle weakness, or confusion, which require immediate consultation with a healthcare provider. There are several kinds of neurological disorders, such as

• Neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, show progressive breakdown of nerve cells.
• Vascular & Cerebrovascular disorders are affecting those blood vessels supplying the brain, including stroke & Aneurysms.
• Seizure disorders feature abnormal electrical activity in the brain, such as epilepsy.
• Autoimmune & inflammatory diseases are attacking the nervous system, & this mainly covers Multiple Sclerosis and Guillain-Barré syndrome.
• The globe is facing certain types of infections, like meningitis and encephalitis
• Subsidiary neuromuscular diseases, including ALS & muscular dystrophy, are also considered severe concerns.

Briefing on Conventional Diagnostic Types for Neurological Disorders

• Clinical neurological examination is an underlying step, which includes a systematic evaluation of cognitive function, cranial nerves, reflexes, motor strength, and sensory processing by a healthcare provider to concentrate the concern.
• Moreover, the widespread adoption of neuroimaging is implementing MRI as a gold standard to visualize soft tissue, structural abnormalities, tumors, and lesions in the brain & spinal cord. While CT scans use X-ray technology to develop cross-sectional images, commonly leveraged for acute situations, such as hemorrhages or strokes.
• Another major approach is electrophysiology, that executes the adoption of EEG (electroencephalogram) supports in recording electrical activity in the brain, generally utilized to diagnose epilepsy, seizures, & sleep disorders. Additionally, electromyography & Nerve Conduction Studies are assessing the health of muscles & the peripheral nervous system.
• Although cerebrospinal fluid (CSF) analysis is performed via a Lumbar Puncture (Spinal Tap) to spur an extraction & the study of fluid for central nervous system infections, inflammation, or diseases, such as multiple sclerosis.

Limitations of Conventional Neurological Diagnostics

A very prominent demerit of conventional diagnostics is a higher dependency on physicians' interpretation for standard neurological examination, which leads to variations & probable bias. Moreover, an expansive adoption of conventional imaging modalities, especially an MRI & CT scan, needs expensive, highly advanced, & specialized machinery & infrastructure, which is a major concern for small-scale settings & can create inconsistency in the utilization. These imaging modalities have a pivotal role in the detection of large-scale issues, such as strokes or tumors, but in the instances of Alzheimer’s disease or Parkinson’s disease, they have limitations. In these cases, imaging modalities lack the clear anatomical changes that happen early.  Alongside, conventional tests usually give delayed diagnoses, which shows the start of treatment is often done after the already major progression of the disease.

Rise of Blood-Based Biomarkers

To overcome the limitations of conventional diagnostics, the global demand for blood-based biomarkers in diverse neurological disorders includes measurable molecules, like proteins or peptides, found in the blood that show fundamental brain pathology. These biomarkers majorly offer a minimally invasive, affordable, and scalable option to spinal taps or brain imaging to support early detection, patient stratification, & treatment monitoring.

There are major types of blood-based biomarkers used to treat the worldwide neurological concerns.

Clinical Applications of Blood-based Biomarkers in Neurological Disorders

Gradually surging the development and adoption of advanced biomarkers in a huge burden of neurological disorders across the different regions, they assist in translating core disease pathology, like amyloid plaques & tau tangles in Alzheimer's disease (AD), directly into blood measurements. At the early disease stage, blood biomarkers enable clinicians to monitor biological modifications, with the temporal continuum of neurological concerns. Biomarkers generally facilitate quantifiable data to track disease progression over time. Apart from this, in case of treatment response, the emergence of disease-modifying therapies, including monoclonal antibodies, has made objective treatment monitoring crucial. In addition, the rigorous clinical trials are focusing on biomarkers with the ability to anticipate the likelihood of clinical events, especially expedited disease recurrence or cognitive decline.

Fujirebio's Vision for the Future of Neurological Diagnostics

In 1950, Fujirebio was established in Tokyo as an eminent player in in vitro diagnostics (IVD) specializing in biomarker development & clinical testing. This firm mainly serves as a key CDMO (Contract Development and Manufacturing Organization) and is popular for its innovative work in neurological, oncologic, and infectious disease diagnostics across the globe.

Fujirebio has been unveiling its specific vision regarding blood-based biomarkers used in a growing number of neurological disorders. They have a goal to move from complex, invasive solutions or expensive imaging modalities to subtle, routine blood draws. Furthermore, Fujirebio’s team has been stepping towards pioneering an end-to-end diagnostic pipeline that extends biomarker discovery, regulatory approval, clinical deployment, and global collaborations. One of the prominent offerings of Fujirebio, their Neurodegenerative Disease Portfolio, is highly broadening into other motor neuron and neurodegenerative conditions. A significant & immersive vision has developed an integration of Fujirebio’s CDMO hardware, early-stage biomarkers from ADx NeuroSciences, and specialized testing, called the LUMIPULSE G immunoassay platform. This platform widely provides end-to-end testing solutions & assistance to clinical research and routine diagnostics. This platform covers strong assays, like the fully automated pTau 217 Plasma Test & NfL Blood Tests, runs on Fujirebio’s global network of LUMIPULSE analysers, ensuring high throughput, reproducibility, & clinical reliability.

Fujirebio’s Technology Portfolio

• LUMIPULSE G Series – This mainly encompasses models such as the mid-to-high throughput LUMIPULSE G1200 & the LUMIPULSE G600II, which are automated, random-access chemiluminescent enzyme immunoassay (CLEIA) analyzers. These models have broader applications for oncology, infectious disease, and neurological testing.
• Lumipulse G Assays – This is characterized by fully automated assays for pTau 217 (both CSF and plasma), NfL (Neurofilament light chain), GFAP, sTREM2, & β-amyloid ratios.
• CanAg Assays – This focuses on advanced tumor marker assays, like CA 125, CA 15-3, CA 19-9, that are available in both manual and automated formats.
• Strip-Based & Manual Assays – Fujirebio is highly offering INNO-LIA and INNO-LiPA, line probe and line immunoassay platforms, especially for the multiparametric confirmation of infectious diseases & neurological subtyping.

From Research to Clinical Practice: Fujirebio’s Commercialization Strategy

Research & Early Discovery (RUO)

A strategy aims at early-stage research biomarkers, such as pTau181, Aβ42/40, and developing targets like NPTX2 & sTREM2 that are initially developed as Research Use Only (RUO) assays. Alongside, the firm is unveiling major collaborations with specialized innovators to unify high-sensitivity platforms early in the discovery pipeline

Clinical Validation & Regulatory Strategy

The emergence of Fujirebio’s clinical solutions involves the execution of multi-site studies, specimen collection, and data integrity management to comply with Good Clinical Practice (GCP) requirements. Also, they are revolutionizing biomarkers into in-vitro diagnostic tests, performing the needed analytical & clinical performance assessments to foster regulatory claims. Fujirebio is majorly securing authorizations from the U.S. FDA, as they cleared a blood-based IVD test for Alzheimer’s diseases firstly.

Commercialization & Global Accessibility

Fujirebio is a CDMO that widely supplies raw materials, customized antibodies, & ready-to-use reagents to worldwide IVD players. They are promoting acquisitions with diverse leading companies, which protect Fujirebio’s critical biospecimens and early-stage biomarker intellectual property, enabling them to manage the development pipeline from raw research to commercial IVD.

Number of Alzheimer’s Disease Cases in 2030 in Diverse Areas & Use of Blood Biomarkers

The above graph represents the number of Alzheimer’s disease cases across the different regions or countries, & further, these cases push studies & clinical trials that are standardized in Chinese cohorts, including simultaneous testing of multiple biomarkers via blood, which can estimate Alzheimer’s with greater than 96% accuracy. Ongoing research activities are demonstrating novel predictive indicators, like circular RNAs in the blood as dynamic markers that anticipate AD progression with accuracy similar to p-tau217.

To overcome the rising issues relevant to neurological disorders across India, India’s prominent labs, like Mahajan Imaging Labs and Metropolis Healthcare, are now providing modern AI-integrated blood tests that screen for p-Tau217 and Beta-Amyloid (Aβ1-42). This enables the detection of pathological changes up to 15 years before clinical symptoms develop.

On the other hand, Chinese researchers at Shanghai Jiao Tong University (SJTU) found specific biomarkers that distinguish Parkinson's disease from MSA.

In the U.S., a National Institutes of Health-funded study published in Nature Medicine identified a set of 34 circular RNAs in the blood that can estimate the onset of Alzheimer's disease symptoms years before they emerge.

To bolster early detection, clinical trials across Europe, such as Denmark, Italy, Spain, Sweden, and the UK, have studied a finger-prick blood test evaluating p-tau217, GFAP (glial fibrillary acidic protein), & NfL (neurofilament light chain).

According to the World Federation of Neurology

On 23 June 2026, the World Federation of Neurology (WFN) introduced World Brain Day 2026, focused on the theme ‘Brain Health: Access for All.’  This global initiative highlights a critical disparity: while neuroscientific expansion is expediting, over 3.4 billion people, i.e. more than 40% of the global population, are currently living with neurological conditions. On this occasion, Professor Tissa Wijeratne, OAM, MD, PhD, Chair of World Brain Day 2026, commented that “World Brain Day 2026 focuses on one of the defining challenges of our time: making brain health accessible to everyone, everywhere.”  While Professor David Dodick, MD, Co-Chair of World Brain Day 2026, explained that, "Access to brain health is a profound global issue. While the disparity with low-income countries remains staggering, with 227 times fewer neurologists per capita, even in high-income countries, cost, primary care and specialist shortages, and overburdened systems prevent billions from receiving essential care. Evidence shows that addressing lifestyle and modifiable risk factors can optimize brain health, meaning prevention, public empowerment, and stronger local policy and resources can make a meaningful difference everywhere."

According to Towards Healthcare, the global blood based biomarkers market size is calculated at USD 7.89 billion in 2024, grew to USD 8.46 billion in 2025, and is projected to reach around USD 15.78 billion by 2034. The market is expanding at a CAGR of 7.24% between 2025 and 2034. The blood based biomarkers market is mainly driven by suitable government encouragement to boost early detection & screening of chronic disorders. While numerous government bodies & regulatory agencies have published guidelines to raise awareness among the general public due to the surging incidences and cases of chronic disorders. Specifically, the World Health Organization (WHO) demonstrates non-communicable diseases as a global threat and launched the ‘2030 Agenda for Sustainable Development.’ Meanwhile, in 2025, North America dominated the blood based biomarkers market due to the growing investments & collaborations among the U.S. & Canadian leaders. Whereas, the Asia Pacific is expected to grow fastest in the market, as China & India are fostering robust R&D hubs, with wider growth of pharmaceutical & biotech sectors.

Latest Collaborations of Fujirebio with Global Partners

• In February 2026, Fujirebio Holdings, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc. & Sysmex Corporation, entered into a sales collaboration for dementia testing.
• In June 2025, Fujirebio, a prominent developer in in-vitro diagnostics, joined with Stanford Medicine to bolster research and innovation in the field of infectious disease testing & focused on speeding up the adoption of ultrasensitive immunoassays.
• In June 2025, Fujirebio Holdings, Inc. acquired all shares of Plasma Services Group, Inc. & reinforced its position as a provider of vital and high-quality biological raw materials to the IVD and life science industries.

Role of Blood Biomarkers in Disease-Modifying Therapies

Patient Selection

Clinicians must ensure the accurate pathological signs of the disease before the prescription of DMTs, particularly targeted biologics, such as anti-amyloid monoclonal antibodies. Whereas, specifically in Parkinson's disease, blood-derived assays measuring α-synuclein exosomes are developing to support stratifying patients and confirming target-specific protein aggregation.

Monitoring Treatment Response

Mainly, blood biomarkers enable dynamic, longitudinal monitoring. However, for anti-amyloid treatments, monitoring longitudinal alterations in blood p-tau217 assists in tracking the clearance of amyloid plaques from the brain, acting as a reliable surrogate for PET imaging results. Implementation of biomarkers enables the titration and real-time adjustment of therapies & further ensures the treatment is striking the purposive biological targets without triggering adverse events. 

Tracking Neurodegeneration & Disease Expansion

Elevated NfL levels are highly utilized to trace disease progression and treatment efficacy across various conditions, such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). On the other hand, increased levels of GFAP in serum show reactive astrogliosis and brain inflammation, which are significant targets for both neuroprotection & anti-inflammatory DMTs.

Resolving Logistical Hurdles

Blood-based biomarkers allow decentralized care, making it easier to screen and monitor patients with complex, long-term therapeutic regimens. These also foster the detection of structural and functional brain changes years before clinical symptoms manifest & enable intervention at a time when the disease can be most efficiently altered.

Competitive Landscape of Blood-Based Neurological Biomarkers

Comparative Analysis: Fujirebio Versus Competitors

Global competitors of Fujirebio are introducing innovations across the blood-based biomarkers sector, which has been extensively boosting market development.

• In June 2026, Sysmex Europe SE announced the availability of the HISCL automated immunoassay system for Alzheimer’s disease blood biomarker testing & facilitates a non-invasive alternative to conventional diagnostic pathways. This approach was developed to provide a rapid & automated solution, particularly for laboratory purpose, with a CE-marked Aβ42/40 ratio assay and a p-Tau217 assay available for research use only.
• In May 2026, Roche received CE Mark for Elecsys® pTau217, a blood test created in collaboration with Eli Lilly and Company and developed to measure the phosphorylated Tau (pTau) 217 protein, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease.
• In March 2026, the Alzheimer’s Drug Discovery Foundation (ADDF) unveiled the third phase of its Diagnostics Accelerator (DxA), led by an additional $50 million in funding that brings the initiative’s total investment to $150 million. This will aim at advancements in next-generation biomarkers, such as blood tests for tau & other co-pathologies, combined multi-marker panels, with AI-assisted tools to impel drug development, allow combination therapies, & expand tailored medicine for Alzheimer’s disease.
• In March 2026, Siemens Healthineers announced that its approaches for brain health research include the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) & Atellica IM Brain Derived Tau (BDTau) assays.
• In March 2026, Neuberg Diagnostics rolled out the Mispa i60 in Chennai for Alzheimer’s screening through a blood test by using a blood sample to detect markers associated with Alzheimer’s disease and is being advanced as an adjunct to clinical study.
• In February 2026, Labcorp made the national availability of the Elecsys pTau-181 test, the first and only blood test approved by the U.S. Food and Drug Administration (FDA) to help in the initial assessment of Alzheimer's disease in the primary care setting.
• In January 2026, Alamar Biosciences, Inc. launched its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay, an innovative solution that allows simultaneous quantitative measurement of five critical blood-based biomarkers related to the Alzheimer's Association recommended guidelines.
• In December 2025, Circular Genomics, Inc. successfully closed a $15 million Series A financing round, supported by Mountain Group Partners, with participation from Poplar Grove Investors, HIP Fund, and the Alzheimer's Drug Discovery Foundation (ADDF). This will expedite the clinical development and commercialization of Circular Genomics' proprietary circRNA biomarker platform for the early detection of Alzheimer's disease (AD) & reshaping the standard of care for all neurological disorders.

How are AI & Certain Integrations Governing Blood Biomarkers in Neurological Disorders?

The use of machine learning models & deep joint-learning frameworks is separating & identifying intricate protein patterns hidden from human analysis. Besides this, AI algorithms are predicting translation from mild cognitive impairment to Alzheimer's with accuracies surpassing 90%. With a focus on subclinical signs, clinicians can treat much earlier in the disease's progression. Eventually, breakthroughs comprising AI solutions integrating blood biomarker profiles with other diagnostic metrics, such as genetic data, wearable sensors, and neuroimaging, to develop extensive patient risk profiles & allow tailored neurology.

Groundbreaking AI systems, including the classifier designed at Washington University in St. Louis, can differentiate between dementia subtypes with over 90% accuracy. Also, serve as pivotal for determining situations where a patient has more than one foundational brain disease simultaneously.

Future Opportunities of Blood-Based Biomarkers Beyond Alzheimer’s Disease

Nowadays, the model has transitioned toward brain-derived blood diagnostics, significantly employing Neurofilament light chain (NfL) to gauge axonal damage and treatment response. Also, the biomarkers industry is experiencing the development of glial fibrillary acidic protein (GFAP) as a vital prognostic indicator for disease progression independent of relapses.

In the instances of Parkinson’s disease (PD), the latest proteomic and transcriptomic workflows, like the analysis of microRNAs & alpha-synuclein exosomes, focused on offering highly specific screening for PD. Besides this, the discovery of these markers enables molecular subtyping, allowing clinicians to personalize disease-modifying therapies to individual patient pathophysiologies.

Globally accelerating prevalence of stroke & traumatic brain injury (TBI) is pushing advances in rapid blood tests that target acute markers, especially GFAP and UCH-L1. This plays a crucial role in early triage and prognostic assessment in emergency settings, which substantially enhances workflow and informs intervention protocols. Additionally, opportunities in Amyotrophic Lateral Sclerosis (ALS) will foster blood-based assays that determine cryptic exon-derived peptides, like those derived from the UNC13A gene, which roll out specific molecular subtypes of ALS.

Regulatory, Reimbursement, & Adoption Challenges

Regulatory Limitations

Analytical sensitivity & specificity, with pre-analytical & analytical differentiations, are impacting the progressive regulatory landscapes for many companies. Especially in the United States, several of the tests are created as Laboratory Developed Tests (LDTs), which results in regulatory burden, necessitating powerful, multi-site clinical validation and longitudinal outcome data to receive full in-vitro diagnostic (IVD) authorization.

Reimbursement Barriers

Industry has been seeking to protect promising CPT or similar localized billing codes, which is a slow, iterative process & needs proof of a wide range of commercial validity. Besides this, especially, the Centers for Medicare & Medicaid Services (CMS) in the US demands robust evidence that a blood test optimizes patient results or successfully changes clinical management. For this establishment, payers necessitate long-term, multi-ethnic, and prospective cohort data, which are still growing.

Adoption Obstacles

Across the world, numerous underlying biomarker studies used small, relatively homogeneous cohorts. Recognition of how systemic comorbidities, age, kidney function, and different racial/ethnic backgrounds impact baseline biomarker cutoffs is important. General practitioners are often facing a shortage of the specific training needed to confidently order advanced tests & ethically secure neurodegenerative risk without specialist backup.

Market Opportunities Through 2035

Through 2035, the blood biomarker industry will replace expensive cerebrospinal fluid (CSF) taps & PET scans, while commercial blood panels for markers such as p-tau217 range from USD 200–400. This cost-effectiveness will launch broader opportunities for routine screening in memory clinics and general practice around the world. Ongoing improvement in assay sensitivity is a major effort moving from centralized labs to local hospitals and specialty clinics. Whereas providers are aiming at miniaturized testing equipment and rapid multi-analyte panels that diagnose conditions, including Parkinson's and multiple sclerosis, from small blood samples.

As rapidly witnessing end-users, many leading pharmaceutical & biotech firms are promoting liquid biopsies and precise tracking of proteins, especially neurofilament light chain (NfL) in blood. This further allows drug innovators to screen patients, ensure target engagement, and measure therapeutic effectiveness in clinical trials quickly and more safely.

Continuous developments of AI algorithms are exploring the integration of blood biomarker results with AI-powered analytics and digital platforms, generating a novel frontier in chronic disease monitoring. Alongside, firms are fostering the unification of biomarker assays with software solutions to offer actionable clinical insights for neurologists.

In the global market, the North America region registered dominance, while the Asia Pacific is predicted to expand at a rapid rate, due to the surging healthcare infrastructure investments & public awareness.

Prospective Outlook of Next-Generation Neurology Diagnostics

Rapid expansion of artificial intelligence, molecular biology, and advanced engineering is forecasting a vast growth in diagnostic imaging valuation through 2035.

Specific applications of AI models are supporting the identification of clear structural and functional anomalies, like earlier microbleeds or metabolic variations in FDG-PET scans, to diagnose complex dementias long before clinical symptoms appear. Furthermore, companies are increasingly establishing multimodal data integration through the reconciliation of neuroimaging data, Next-Generation Sequencing (NGS) data, and electronic health records (EHRs). Mainly, AI-enabled clinical decision support systems assist in anticipating stroke risks & customize neuro-oncology treatment.

The widespread demand and development of precision intervention is spurring the serum Neurofilament Light Chain (NfL) assay that enables clinicians to monitor active neuroinflammation and trace disease progression in issues, including relapsing-remitting multiple sclerosis (RRMS) via a subtle blood draw. To elevate early screening, modern biomarkers are fostering tracking vascular plaque buildup & prior inflammatory responses in the blood, which are being evolved into primary care screening tools to grasp age-related cognitive decline decades in advance.

An affordable diagnostic is targeted multi-gene panels for paediatric neuromuscular disorders, where technologies, such as nanopore sequencing, are expected to make full WGS highly inexpensive. Additionally, the incorporation of next-gen genomic workflows is assessing non-coding elements, RNA modifications, and intronic growth that were previously omitted from traditional analysis. This further supports mapping the precise genetic underpinnings of complex diseases, such as epilepsy, migraine, & Parkinson's disease.

Another future outlook is spotlighting remote monitoring & advances in wearables. Industries are greatly revolutionizing devices from compact, in-lab caps into lightweight, wireless, multi-channel headsets. Innovations in sophisticated setups are allowing cloud-connected seizure tracking & also enable clinicians to make persistent observation of brain activity in real-time. Besides this, the progression & demand for remote monitoring are launching machine learning (ML) models that integrate automated speech analysis & natural language processing (NLP) to determine cognitive decline by recording alterations in a patient's natural daily speech patterns.

Projection of next-generation neurological diagnostics in Brain-Computer Interfaces (BCIs) is shifting from episodic, hospital-bound measurements into consistent, AI-enabled, & widely unified digital diagnostics. This breakthrough pushes the prediction, mapping, & treatment of complex Central Nervous System (CNS) disorders, like epilepsy, Alzheimer’s, and severe motor or psychiatric conditions, often years before clinical symptoms completely occur.

Investor Perspective on Blood-based Neurology Biomarkers

In 2026, the biomarkers industry has been witnessing rapid growth, as investors are heavily investing in platforms that detect minimal quantities of blood-based proteins, such as NfL, p-tau, & GFAP. This drives key firms to promote & advance ultra-sensitive detection technology utilised in worldwide labs. Many investors are looking for robust collaborations, including outsourcing to CROs that cover standardised diagnostic platforms, which yield notable, contracted revenue from drug pioneers. However, pharmaceutical leaders are demanding biomarker testing for patient stratification in clinical trials, evaluating efficacy, & pharmacodynamic monitoring.

A global burden of geriatric population, a rise in incidence of neurodegenerative conditions, like Alzheimer's and Parkinson's disease, fuels the demand for novel therapies & diagnostics. In these circumstances, blood biomarkers allow asymptomatic, earlier detection long before severe cognitive decline appears & establishes a high-volume, recurring market for routine health checkups & preventive neurology.

Conclusion

Fujirebio is a well-established CDMO that has been aiming at the diverse key drivers of blood-based biomarkers used in various neurological disorders. Globally expanding ageing population is assisting in the unveiling of disease-modifying therapies for Alzheimer's, which needs highly precise, accessible tests to monitor patient response & tau or amyloid pathology. Fujirebio’s ongoing high-throughput automation & integrated ecosystem, including the LUMIPULSE G platform, is helping laboratories to perform assays, especially the pTau 217 Plasma and NfL Blood, with increased effectiveness. To raise or bolster commercialization of novel blood neurology biomarkers, Fujirebio is entering into strategic partnerships with various kinds of players, like Biogen & Beckman Coulter.